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ABSTRACT 
Oxytocin As a Treatment for Addiction: The Effects of Exogenous Oxytocin on  
Heroin Taking and Seeking in Male Rats 
  Janie Duchesneau 
Drug addiction is characterized by recurring episodes of relapse and has a profound 
impact on individuals’ well-being as well as our economic and healthcare systems. Although 
many efforts have been put into developing solutions to treat drug addiction, an effective long-
term treatment has yet to be found. Previous animal studies indicate that exogenous oxytocin 
(OXT) holds potential to treat and reduce relapse, withdrawal and help drug cessation. More 
particularly, a decrease in psychostimulant drugs (e.g., cocaine and methamphetamine) 
consumption has been noted while earlier studies also suggested a similar role for OXT in opiate 
drugs (e.g., morphine and heroin) reward and withdrawal.  
In light of those studies, our objective was to continue investigating the role of OXT in 
inhibiting heroin self-administration (SA) as well as attenuating relapse by using an animal 
model of stress-induced reinstatement. We examined the effects of acute and chronic 
administrations of OXT on heroin SA and the reinstatement of extinguished heroin seeking in 
male rats. Rats were tested under fixed-interval 20 s (FI-20 s) and progressive-ratio (PR) 
schedules of reinforcement in order to assess heroin intake. Results suggest that OXT did not 
attenuate heroin taking during the SA sessions under various schedules of reinforcement. Next, 
we tested the effect of OXT on stress-induced reinstatement of extinguished heroin seeking, by 
using yohimbine (YOH) as our pharmacological stressor. Contrary to our expectations, central 
administration of OXT did not attenuate yohimbine-induced reinstatement. In conclusion, 
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contrary to recent findings with psychostimulant drug-trained rats and earlier reports with heroin-
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General Introduction 
Defined as a chronic, relapsing disorder, drug addiction is characterized by compulsive 
drug taking and drug seeking (O’Brien & McLellan, 1996). It is one of today’s most prevalent 
neuropsychiatric disorders (Piazza & Deroche-Gamonet, 2013). Drug addiction is multifaceted 
and, even though it results in a wide range of dysfunctions and negative impacts on motivation, 
emotions, learning and behaviours, individuals suffering from this disorder will maintain their 
drug usage despite its negative effects (Piazza & Deroche-Gamonet, 2013). For example, 
individuals who display recurrent drug use will suffer consequences preventing them from 
fulfilling major role obligations or induce precarious situations when under the influence of a 
substance. Drug addiction might also create pharmacological tolerance and induce withdrawal 
symptoms and lead to persistent social problems generated by the effects of the abused 
substance(s) (APA, 2013).  
At the macro level, drug addiction causes a substantial drain on Canada’s economy (Rehm 
et al., 2006) by directly affecting both the healthcare and the criminal justice systems, and by 
indirectly affecting work-related productivity. A study published in 2006 by the Canadian Centre 
on Substance Abuse estimated the overall societal cost of illegal drugs to be 39.80 billion dollars 
per year (Rehm et al., 2006). Illicit drugs account for 20.70 % of those costs, representing a total 
of 8.20 billion dollars (Rehm et al., 2006). In particular, heroin use has been a considerable public 
health issue for Canada with a known population of 60 000 to 90 000 users, aged 15 to 64 
(Fischer et al., 2002). 
Heroin users have a greater likelihood of morbidity, mortality and disability in 
comparison to the general population (Fischer et al., 2002), and 40 to 60 % of drug abusers who 
successfully cease to take drugs will relapse into their drug taking habit during the following year 
(McLellan et al., 2000). Relapse can be triggered by cues directly associated with the abused drug 
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(e.g., syringes, white powder, etc.) or by environmental cues such as being exposed to a specific 
location where someone used to take drugs, or re-exposure to the drug itself. Stress such as 
divorce, death of a relative, or financial difficulty is also a factor known to trigger relapse (Hser 
et al., 2000).  
Its principal characteristics and the plethora of undesirable consequences suggest a grim 
reality: Drug addiction, and more specifically heroin usage, is still a pressing social issue, and an 
efficient and lasting treatment has yet to be found. Various behavioural strategies and 
pharmacological treatments have been suggested (e.g., Jain, Majumder, & Gupta, 2013; NIDA, 
2011; Volkow et al., 2007), but with limited long-term success. To date, the most effective 
treatment programs have included various elements, each focusing on a specific aspect of the 
disorder and its related consequences. For example, treatments must not only address and treat 
the disorder itself, but also the more indirect negative consequences such as interpersonal 
conflicts and job loss. In fact, drug addiction treatment should empower addicts to maintain a 
drug-free regimen and help them achieve an adequate level of productivity in their family, at 
work, and in society (NIDA, 2011). However, due to its chronic and relapsing nature, drug 
addiction has been shown to be incredibly difficult to treat in the long term, and achieving and 
maintaining a drug-free life may thus require many attempts.  
Various pharmacological treatments are available as treatment for addiction to various 
drugs and drug classes. Some treatments target the psychoactive drugs or their receptors in an 
effort to block their effects. For example, active immunization with vaccines showed treatment 
potential against nicotine (Pentel & LeSage, 2014), cocaine as well as methamphetamine (Shen, 
Orson, & Kosten, 2012), and pharmacological modulators (i.e., receptor antagonists or partial 
agonists) such as naltrexone that block euphoric effects associated with heroin, nicotine, and 
alcohol intake (NIDA, 2011). A different approach is substitution/drug replacement therapies, 
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including transdermal patches, chewing gum, inhalers, nasal spray, and lozenge used for nicotine 
addiction (Jain, Majumder, & Gupta, 2013). In heroin addicts, methadone and buprenorphine are 
commonly used as substitution for opiates (Mattick, Breen, Kimber, & Davoli, 2014). At present, 
however, the reported effects seem to be only mildly effective in the long term. Consequently, 
many former drug addicts, even after years of abstinence, will relapse and continue this 
deleterious cycle of drug taking and drug seeking (McLellan et al., 2000; Siegel, 2002). In the 
present thesis, we sought to investigate a new method to treat heroin addiction as it is has been 
shown to have the greatest rate of mortality among drug users and that neither methadone nor 
buprenorphine seem to cure heroin users from their addiction.   
 
Oxytocin  
Oxytocin, a neuropeptide primarily known for its role in parturition & lactation (Lee et al., 
2009), has been reported to also affect social behaviours, learning and memory. Importantly, 
earlier research suggested that OXT had the potential to inhibit the development of tolerance 
(Kovács & Van Ree, 1985; Kovács & Telegdy, 1987), and to reduce both withdrawal symptoms 
and self-administration of opiates in rodents. Recent studies have also reported a decrease in the 
motivation to seek and self-administer stimulant drugs such as methamphetamine (Carson et al., 
2010; Westenbroek et al., 2013) and cocaine (Leon et al., 2016; Zhou et al., 2014).  
Oxytocin (OXT) has been widely studied since Dr. Vincent du Vigneaud isolated the 
molecule and synthesized it in its active form for the first time more than four decades ago (du 
Vigneaud et al., 1953). Oxytocin’s major expression site is situated in the hypothalamus, more 
specifically in the magnocellular neurons of the hypothalamic paraventricular (PVN) and 
supraoptic (SON) nuclei (Gimpl & Fahrenholz, 2001; Marazzti et al., 2008; Rubin & Pfaff, 
2009). In response to a plethora of stimuli such as mating, pregnancy, parturition, suckling 
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(Rubin & Pfaff, 2009), social bonding, and some types of stress, oxytocin is released from the 
posterior pituitary into the blood stream (Gimpl & Fahrenholz, 2001; Rubin & Pfaff, 2009). In 
addition to the hypothalamic projections of oxytocin, oxytocinergic neurons display widespread 
projections throughout the central nervous system and both originate and affect regions such as 
the basal ganglia, the limbic system, the thalamus, the brainstem, the spinal cord and other 
cortical regions (Gimpl & Fahrenholz, 2001; Rubin & Pfaff, 2009). Oxytocin is also synthesized 
in peripheral tissues such as the uterus (Gimpl & Fahrenholz; Rubin & Pfaff, 2009), the ovary 
(Rubin & Pfaff, 2009), the mammary gland (Rubin & Pfaff, 2009), the testis (Gimpl & 
Fahrenholz, 2001; Rubin & Pfaff, 2009), the liver (Rubin & Pfaff, 2009), and the heart (Gimpl & 
Fahrenholz, 2001; Rubin & Pfaff, 2009). This neurohormone has, to date, one known receptor: 
OXTR. The OXTR is a G protein-coupled receptor that is primarily coupled via Gq proteins to 
phospholipase C (Rubin & Pfaff, 2009) and is widely distributed throughout the brain, including 
in reward-related areas such as the VTA and nucleus accumbens (Love, 2013).  
 
Oxytocin as a potential treatment for drug addiction 
Oxytocin, a neuropeptide primarily known for its role in ensuring homeostasis, 
reproductive success and social behaviours, oxytocin has been shown to be involved in both 
learning and addiction processes (Sarnyai & Kovács, 2013). Importantly, earlier research 
suggested that OXT had the potential to inhibit the development of tolerance (Kovács & Van 
Ree, 1985; Kovács & Telegdy, 1987), and to reduce both withdrawal symptoms and self-
administration of opiates in rodents. Recent studies have also reported a decrease in the 
motivation to self-administer and to seek stimulant drugs such as methamphetamine (Carson et 
al., 2010; Westenbroek et al., 2013) and cocaine (Leong et al., 2016; Zhou et al., 2014). These 
reports also suggested that neuropeptides, more specifically OXT, could modulate forms of 
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neuroadaptation such as learning and memory processes (e.g., Davis et al., 2014) and addiction 
(e.g., Carson et al., 2010; Carson et al., 2013; Sarnyai et al., 1990; Sarnyai & Kovács, 1994; 
Sarnyai, 2011; Thompson et al., 2007). Previous studies on the role of OXT in social behaviours 
(e.g., Sobota et al., 2015) and learning processes (e.g., Campbell-Smith, Holmes, Lingawi, 
Panayi, & Westbrock, 2015) have lead scientists to believe that OXT could also mediate pro-
social effects of drugs of abuse such as MDMA (i.e., ecstasy) (Sarnyai & Kovács, 2013). 
Thompson et al. (2007) suggested that the effects of OXT on addiction, despite being limited, are 
perhaps related to the heightened reward obtained from social interactions instead of the reward 
induced following drug usage. They have also suggested that positive and pro-social interactions, 
when taking place outside a drug context, could serve as a protective factor against drug use. 
However, positive or negative social interactions taking place within a drug-related context might 
interact with other factors and either precipitate or inhibit drug consumption. Other research 
suggests that OXT mostly inhibits memory consolidation, retrieval and other learning and 
memory processes (Sarnyai & Kovács, 2013). As drug addiction is often referred to as a type of 
pathological learning, it seems reasonable to assume that OXT might inhibit or reduce drug-
related responses.  
 Dopamine (DA), a monoamine neurotransmitter, is thought to have a central role in the 
reinforcing effects of drugs of abuse (Volkow et al., 2007). Specifically, the mesolimbic 
dopaminergic system is strongly involved in goal-oriented behaviours (Iversen et al., 2009), 
attention (Iversen et al., 2009), reward (Iversen et al., 2009; Berridge, 2007), and addiction 
(Volkow et al., 2007). The dopaminergic neurons in the mesolimbic pathway originate from the 
ventral tegmental area (VTA) and project to the nucleus accumbens (NAc) and to the prefrontal 
cortex (PFC) (Wise, 2002). Stimulants such as amphetamine and cocaine act on the dopamine 
transporter and directly increase dopaminergic transmission in the nucleus accumbens (Wise, 
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2002; Koob, 2008) while opiate drugs inhibit GABA-ergic neurons that, in turn, disinhibit 
dopaminergic neurons in the VTA (Koob, 2008).  
This central neuromodulator has a vast number of effects on central nervous system 
functions, such as mood (Baskerville & Douglas, 2010), behaviour (Baskerville & Douglas, 
2010), and pair-bonding consolidation (Liu & Wang, 2003). However, recent studies have raised 
an interesting observation: Individuals suffering from dopamine-related disorders like 
schizophrenia (Rosenfield, Lieberman, & Jarskog, 2010), anxiety disorder (Abi-Dargham, 2012; 
Amico et al., 2004) and addiction (Sarnyai & Kovács, 2013) also had irregular levels of 
peripheral and central oxytocin (Baskerville & Douglas, 2010). Consequently, oxytocin has been 
suggested to be a pivotal neural substrate that interacts with dopamine systems (Baskerville & 
Douglas, 2010; Liu & Wang, 2003). Such interactions have been revealed to modulate 
behaviours such as social affiliation, mating and drug-altered locomotion (Kovács et al., 1990). 
Moreover, it has been suggested that oxytocin mediates the mesolimbic dopamine system during 
drug addiction processes (Baskerville & Douglas, 2010; Kovács et al., 1990; Sarnyai et al., 1990; 
Sarnyai et al., 1992; Sarnyai & Kovács, 1994; Sarnyai & Kovács, 2013). Morphological and 
functional studies have shown that oxytocin acts as a neuromodulator in (meso-)limbic structures 
and spinal regions (McGregor, Callghan, & Hunt, 2008). Such structures, like the nucleus 
accumbens, the ventral tegmental area, and the hippocampus, are innervated with oxytocinergic 
neurons (Gimpl & Fahrenholz, 2001; Love, 2013). These structures have previously been shown 
to be effective in mediating drug reward and addiction (Wise, 2002). 
 
The importance of animal models of drug addiction 
A major challenge of addiction research has been to develop animal models in order to 
study the multifaceted aspects of drug addiction. The complexity of this neuropsychiatric disorder 
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makes it highly complicated to study its etiology and underlying neurocircuitry in humans, which 
stresses the importance of preclinical animal models in elucidating the neuropathophysiology of 
addiction (Piazza & Deroche-Gamonet, 2013). Drug addiction affects multiple brain circuits that 
are strongly involved in reward, motivation, learning, and memory (Iversen et al., 2009; NIDA, 
2011). Clearly, understanding the neural mechanisms associated with drug-related behaviours 
such as drug taking, drug seeking, and relapse necessitates a cellular and subcellular examination 
of neuronal systems (Yap & Miczek, 2008). Animal models of drug addiction thus provide 
pivotal insight into the conditions and mechanisms affecting the multifaceted aspects of this 
disorder.  
Numerous empirical studies have used animal models of drug addiction. Among the 
advantages to using animal models is the opportunity to investigate the different phases of the 
drug addiction cycle (Deroche-Gamonet & Piazza, 2014), to assess the reinforcing properties of 
novel drugs (O’Connor et al., 2010), to assess the abuse potential of a drug (Haney & Spealman, 
2008), and to achieve a better understanding of the neural systems that are involved in the 
development and maintenance of the disorder (O’Connor et al., 2010). Based on these findings, 
we used a distinctive feature of the drug self-administration model that maximizes the internal 
validity and reproducibility of the design while aiming at a holistic approach of significant 
relevance to human situations as proposed in Sanchis-Segura & Spanagel (2006). The self-
administration model consists of training an animal – in our case, a rat – to perform an operant 
behaviour leading to the consumption of a drug by different routes of administration (i.e., 
intravenous infusion of heroin). In addition to the “choice” made by the animal to self-administer 
a given drug – in our case, heroin –, the route by which the drug is administered is pivotal to its 
effects on both organism and behaviour. For example, there is a shorter latency between the time 
an animal self-administers a drug intravenously (i.e., performs an operant behaviour and then 
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receives a drug through an intravenous catheter) and the experienced physiological and 
psychoactive effects of the drug compared to the experimenter injecting it in the periphery, either 
by intraperitoneal (IP) or subcutaneous (SC) injections. The association made between operant 
behaviour (i.e., drug seeking and consumption) and the perceived effects following it (i.e., 
euphoria, relaxed state, etc.) resembles human drug usage. Furthermore, the animal has complete 
control over the amount of drugs consumed. In other words, the total drug dose administered 
within a session is dependent on the behaviour of the rat (Sanchis-Segura & Spanagel, 2006; 
O’Connor et al., 2010). Consequently, the self-administration procedure plays a fundamental role 
in advancing our understanding of the abuse liability of a drug and the reinforcing effects it has 
on the organism. 
 A vast number of self-administration studies have used simple fixed-ratio (FR) schedules 
of reinforcement (Arnold & Robert, 1997). A fixed-ratio schedule is a schedule where a response 
(e.g., a lever press) is reinforced once a specific number of responses has been performed. For 
example, if a rat were under a fixed-ratio 1 (FR1) schedule of reinforcement, it would have to 
respond once (i.e., pressing a lever) to receive reinforcement (i.e., drug delivery). Similarly, the 
fixed-interval ratio means that a reward will be made available when a response is performed 
after a certain amount of time has elapsed since the last reinforcement delivery (Cosgrave, 2016). 
Those fixed schedules are useful for exploring behavioural patterns of drug intake and for 
teaching new behaviours. However, those fixed schedules of reinforcement seem inappropriate 
when assessing changes in the reinforcing effects of drugs, leading to several issues associated 
with the interpretation of the resulting fixed-ratio data (Arnold & Roberts, 1997). Indeed, studies 
using a fixed-ratio schedule of reinforcement base their interpretation on the changes in the rate 
of self-administration. However, those changes in rate of self-administration under a fixed ratio 
might originate from an alteration in relation to a greater increase in drug tolerance (due to the 
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high number of drug infusions per session), which in turn would render the shifts in rats’ drug 
self-administration more tenuous to interpret (Roberts & Bennett, 1993).  
For these reasons, a progressive-ratio (PR) schedule is better suited to studying and 
understanding the reinforcing properties of stimulant and opiate drugs (Arnold & Roberts, 1997; 
Chiodo, Läck, & Roberts, 2008). Similar to a fixed ratio, a progressive-ratio schedule is described 
as a schedule of reinforcement used in operant conditioning settings when an animal (i.e., a rat) is 
trained to produce an operant response (e.g., pressing a lever) in order to obtain a reinforcer (e.g., 
a drug infusion or natural reward delivery). However, following each drug delivery, the number 
of lever presses required to receive the next drug infusion is increased until the rat ceases to 
engage in self-administration or lever pressing for a prolonged period of time. This state is called 
breakpoint. An important factor regarding breakpoint is the fact that it is dose-dependent, hence 
allowing for changes in the dose-response curve to be studied. During the early part of a self-
administration session under progressive ratio, the response ratios are quite small, meaning that 
lever presses are regularly reinforced by drug infusions. As the name suggests, the lever pressing 
requirements progressively increases until it exceed the reinforcing efficacy of the drug, and lever 
responding ceases (Arnold & Roberts, 1997). This designates the breakpoint within a single self-
administration session. The breakpoint under the progressive-ratio schedule is thus used as an 
assessment of the rat’s motivation to self-administer a drug (Arnold & Roberts, 1997; Chiodo et 
al., 2003).  
 
Oxytocin treatment in animal model of drug addiction 
Studies performed since the early 1980s have tested oxytocin as a potential treatment for 
opiate addiction using animal models (e.g., Ibragimov et al., 1987; Kovács & Van Ree, 1985; 
Sarnyai et al., 1990). Those findings suggested that oxytocin administration could influence 
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opiate (heroin and morphine) self-administration as well as the development of tolerance to 
various effects of opiates, cocaine and alcohol (Sarnyai et al., 1992; Kovács et al., 1998). This 
includes, for example, the attenuation of behavioural adaptations (tolerance of stereotyped 
sniffing) following a repeated cocaine administration (Sarnyai et al., 1992). In addition, similar 
results have been reported in relation to stimulant drugs. In fact, treatment with exogenous 
oxytocin was reported to inhibit cocaine-induced locomotor hyperactivity, exploratory activity, 
and stereotyped behaviours (Sarnyai et al., 1992; Sarnyai & Kovács, 1994). Although oxytocin 
also seemed to facilitate cocaine sensitization (Sarnyai et al., 1992), it was also noted that the 
neuropeptide inhibited cocaine tolerance and cocaine self-administration (Sarnyai & Kovács, 
1994).  
 More recently, Carson et al. (2010) studied self-administration, locomotor hyperactivity 
and relapse in methamphetamine-trained rats. Rats were first trained to self-administer 
methamphetamine on a FR1 schedule of reinforcement and then tested on a progressive-ratio 
schedule. Both medium (0.30 mg/kg; IP) and high (1.00 mg/kg; IP) doses of oxytocin resulted in 
reduced motivation to self-administer methamphetamine whereas only the low (0.10 mg/kg; IP), 
medium and high doses of exogenous oxytocin reduced locomotor hyperactivity within the self-
administration period (Carson et al., 2010). Although the extent to which oxytocin crosses the 
blood-brain barrier is still unclear (Gimpl & Fahrenholz, 2001), the effect of oxytocin reported 
above was obtained following peripheral injections of the polypeptide, extending previous 
research that had shown similar drug-related behavioural effects following a central (i.e., ICV) 
administration of oxytocin (Kovács et al., 1998). While most of the studies described above 
tested the effects of oxytocin in male rats, Westenbroek et al. (2013) showed preliminary data 
suggesting that female rats that were chronically treated with oxytocin (0.30 mg/kg; IP) for a 
period of 14 days displayed reduced motivation to self-administer methamphetamine. Similarly, 
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other studies have reported that acute peripheral OXT reduced cocaine SA and active lever 
responses as well as reduced cocaine taking and seeking, and cocaine-induced locomotor activity 
in females (Leong et al., 2016), and a decrease in cocaine taking in males (Zhou et al., 2014), 
thus further supporting OXT as a potential drug therapies for addiction.  
As mentioned above, even with the plethora of studies on drug addiction and the urgent 
need for a treatment, no long-term solution has been established yet. However, the few studies 
that have specifically investigated the role of oxytocin in drug addiction have shown potential in 
treating it. While those promising results have mostly been shown in stimulant drugs such as 
cocaine (Sarnyai et al., 1992; Sarnyai et al., 1991; Zhou et al., 2014; Leong et al., 2016) and 
methamphetamine (Carson et al., 2010; Carson et al., 2013; Westenbroek et al., 2013), previous 
research suggests similar effects of oxytocin treatment in heroin addiction (Kovács et al., 1985).  
 
The current study 
No studies to date have investigated the behavioural effects of exogenous oxytocin 
administration on heroin self-administration under both a fixed-interval (20 s) and a progressive-
ratio schedule of reinforcement. In addition, the effects of treatment with oxytocin on the 
reinstatement of extinguished heroin seeking, a model for drug relapse, have not been previously 
investigated. Given the gap in our knowledge about the consequences of treatment with 
exogenous oxytocin on heroin taking and seeking, we explored the effects of acute (chapter 1) 
and chronic (chapter 2) oxytocin administration on heroin self-administration under FI-20 s and 
PR schedules of reinforcement. In addition we have investigated the effects of an acute (chapter 
1) and chronic (chapter 2) treatment with oxytocin on yohimbine-induced reinstatement of heroin 
seeking, an animal model of stress-induced relapse to drugs (Shaham, Shalev, Lu, de Wit, & 
Stewart, 2003). 
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General Methods 
Subjects  
 Male Long Evans rats weighing 300-350g (Charles River, St-Constant, QC) were used in 
all the experiments. Following their arrival at the animal care facility (ACF), rats were housed in 
pairs and handled for one week under reverse light/dark conditions (lights off at 9:30 a.m.). Rats 
then underwent intravenous (IV) catheterization and the intracerebroventricular (ICV) 
cannulation surgeries. Rats were returned to the ACF where they were single-housed in a 
shoebox cage and given two days of recovery. Following this recovery period, each rat was 
transferred into an operant-conditioning chamber designed for drug self-administration (SA). 
After a day of habituation to their new environment, the rats started heroin SA training. During 
training and extinction phases (see below), rats had unlimited access to food and water. Rats were 
treated according to the Canadian Council on Animal Care guidelines, and the Concordia 
University Animal Research Ethics Committee granted approval for all experiments. 
 
Surgical procedures 
To allow for heroin SA, all rats were implanted with IV silastic catheters (Dow Corning, 
Midland, MI, USA) under ketamine and xylazine anaesthesia (90.0 + 13.0 mg/kg; intraperitoneal 
[IP]). The catheter was inserted into the right jugular vein of the rat and then sutured to the vein. 
After securing the catheter to the vein, the silastic tubing was subcutaneously passed to the top of 
the head where it was attached to a modified 22-gauge cannula (Plastics One Inc., Roanoke, VA, 
USA). In addition, a 22-gauge unilateral cannula (Plastics One Inc., Roanoke, VA, USA) 
targeting the lateral ventricles was implanted in either right or left hemisphere (counterbalanced) 
to enable the ICV OXT injections (AP: -0.5; ML: ±1.3 DV: -3.0 mm, in relation to Bregma). The 
cannula was fixed on the rat’s skull with dental cement and five screws (Boulonnerie de Montréal 
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Inc., Laval, QC). Before surgery, rats were injected with saline (0.90 %; CDMV, Saint-
Hyacinthe, QC) and penicillin (450,000 IU/rat; CDMV, Saint-Hyacinthe, QC) in order to hydrate 
and prevent infection. After surgery, rats were subcutaneously (SC) administered saline and 
ketoprofen (5.0 mg/kg; CDMV, Saint-Hyacinthe, QC) to hydrate and reduce pain. Catheters were 




Rats were housed in operant-conditioning chambers (Coulbourn Instruments, Whitehall, 
PA, USA; 29.00 cm x 29.00 cm x 25.50 cm) for the complete duration of the experiments. Sound 
attenuating chambers enclosed all operant chambers to reduce external sounds. Operant-
conditioning chambers had a metal grid floor, a reusable waste pan, a Plexiglas door and a metal 
ceiling that allowed access to the drug harness system. Two retractable levers (Coulbourn 
Instruments, Whitehall, PA, USA) were located on the same sidewall, 11 cm above the grid floor. 
Presses on the active lever led to the heroin delivery (0.05 or 0.10 mg/kg/infusion) and the 
activation of the cue light/tone complex for 20 s. Presses on the inactive lever had no 
programmed consequences. The location of the active and inactive levers was counterbalanced 
between the chambers. The white cue-light (Coulbourn Instruments, Whitehall, PA, USA) was 
positioned just above the active lever, and the tone module (Sonalert, 2.90 KHz, Coulbourn 
Instruments) was installed above the active lever, close to the chamber ceiling. The infusion 
pump (Razel Single Syringe Pump, Razel Scientific Instruments, Fairfax, VT) was situated 
within the enclosure of the wooden compartment. Each infusion pump had a 20 ml syringe 
connected to a swivel that was then connected to the catheter via Tygon tubing (Norton 
Performance Plastics, Akron, OH, USA; OD 0.06, ID 0.02) and a liquid swivel (Instech, Boulder, 
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CO, USA). The Tygon tubing inside the operant-conditioning chamber was protected by a metal 
spring. A computer system (Graphic State 3.02, Coulbourn Instruments) controlled the chambers 
and recorded all infusions and lever responses. 
 
Drug 
Heroin (diacetylmorphine hydrochloride; National Institute for Drug Abuse, Research 
Triangle Park, NC, USA) was dissolved in sterile saline (5.00 mg/ml) to be diluted again with 
saline, for each rat (0.05 and 0.10 mg/kg/infusion). Oxytocin (OXT) lyophilized powder (50 IU; 
Sigma-Aldrich, St-Louis, MO) was dissolved in sterile saline (0.50, 1.00, 2.50 μg/rat [ICV]; 0.30, 
1.00 mg/kg [IP]).  
 
Procedure 
Training. First, rats were introduced to their individual operant-conditioning chamber for 
a 24-h period (habituation). Following habituation, rats were trained to self-administer heroin for 
10 days under a fixed-interval 20 s schedule of reinforcement (FI-20 s). Training sessions were 3 
hours each, three times a day, with an interval of three hours in between each self-administration 
period. Following a 10-day SA training under a FI-20s, rats were switched to a PR schedule of 
reinforcement (one 5-h PR session per day). All self-administration training sessions were set to 
start immediately after the light went off (9:30 a.m.). For training under FI-20 s schedule of 
reinforcement, both retractable levers were extended at the beginning of the first daily session, 
the house light was on, and the cue light and tone complex were activated for 30 s. The inactive 
lever was not retracted for the next 23 h, to allow better dissociation between the levers. For 
training under PR schedule of reinforcement, both levers were retracted at the end of the 5-h self-
administration session. The infusion pump was activated (5 s, 0.13 ml/infusion) following one 
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press on the active lever (FI-20 s) or following 2, 4, 6, 9, 12, 15, 20, 25, 32, 40, 50, 62, 77, 95… 
presses on the active lever (PR). The progressive ratio equation was calculated as follows: 
response ratio = (5 x e(0.2 x infusion number)) - 5 (Roberts & Bennett, 1993). All numbers were rounded 
to the nearest integer function. A 20 s timeout period always followed the activation of the 
infusion pump, during which all responses were recorded, but not reinforced, and the light/tone 
complex cue remained on. 
 
Test days. On test days, rats were removed from the operant-conditioning chambers and 
injected with OXT approximately 20 minutes prior to their SA session before the beginning of 
the session. Intracerebroventricular injections were performed using a micro infusion pump 
(Harvard Apparatus Model 11 Syringe Pump) over a 2-minute period at 1.0 μl/min for final doses 
of 0.30 μg/rat (chapter 2), 0.50 μg/rat (chapter 1), 1.00 (chapter 2) or 2.50 μg/rat (chapter 1) and 
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Introduction 
The regulation and functions of he neuropeptide OXT have been under scrutiny more than 
a century (Love, 2013). There are now clear indications that OXT impacts dopamine in the 
mesocorticolimbic system leading us to investigate its impact of reward and motivation (Love 
2013). Earlier studies have explored the effect of exogenous OXT on drug intake as 
neurohypophyseal peptides have been tested to alter the reinforcing properties of opiates (Kovács 
et al., 1985a). Such studies have first investigated the role of acute exogenous OXT on naïve- and 
heroin-trained rats using an animal model of addiction using heroin self-administration (Kovács 
et al., 1985a; Ibragimov et al., 1987). Findings suggested that exogenous OXT decreased heroin 
SA on rats that were made tolerant to the drug, but not in experimentally naïve rats (Kovács et al, 
1985). Other studies showed that oxytocin could also diminish heroin tolerance, and 
simultaneously reduce heroin intake (Kovács & et al. 1985b). More recent studies have shown 
that carbetocin, an OXT analogue, was effective in reducing priming-induced reinstatement of 
extinguished morphine conditioned place preference (Georgiou et al., 2015). Other recent studies 
have shown OXT to be effective in reducing both methamphetamine SA (Carson et al., 2010) and 
methamphetamine-induced reinstatement of methamphetamine seeking in male (Carson et al., 
2010) and female rats (Cox et al., 2013). Other research has found similar positive results on the 
effects of OXT and cocaine SA (Zhou et al., 2014; Leong et al., 2016) as well as cocaine-primed 
(Zhou et al., 2014) and cue-induced reinstatement of extinguished cocaine seeking in both males 
(Zhou et al., 2014) and females (Leong et al., 2016). 
Interestingly, OXT has been shown to be a robust anxiolytic and anti-stress factor of the 
brain (Slattery & Neumann, 2010). Considering that most of the influential theories of drug 
addiction claim that stress plays a significant role in increasing drug intake and relapse (Sinha, 
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2001) and the high ratio of heroin users relapsing over a prolonged withdrawal period (O’Brien, 
1997), research investigating the effect of OXT on stress-induced relapse is more relevant than 
ever. The drug reinstatement procedure, one of the most widely used models for relapse in 
animals, includes many reinstatement methods, such as drug priming-induced reinstatement, cue-
induced reinstatement, and stress-induced reinstatement (Shaham, Shalev, Lu, de Wit, & Stewart, 
2003). In order to test for drug reinstatement, rats must first undergo a consistent drug SA 
regimen. They will then have to experience an extinction phase until they reach a specific 
criterion (< 15 lever responses). During the extinction phase, the heroin is not unavailable which 
will ultimately decrease responses on the lever previously associated with the drug. Finally, the 
rats will be faced with a stressor in order to induce reinstatement of the extinguished drug seeing.  
While most recent studies investigating the impact of OXT on drug taking and drug 
reinstatement choose acute, systemic (i.e., IP) OXT injections, here, we present a novel 
investigation of the role of acute exogenous OXT on heroin self-administration under different 
schedules of reinforcement (FI-20 s and PR), using different doses of heroin (0.05 or 0.10 
mg/kg/infusion) and OXT (0.50 and 2.50 μg/rat [ICV]; 0.30 and 1.00 mg/kg [IP]). Then, 
considering the anxiolytic properties of OXT, we aimed to investigate its behavioural impact of 
acute OXT doses on yohimbine-induced reinstatement of extinguished heroin seeking. We chose 
yohimbine, a pharmacological stressor, due its robust effect at promoting relapse in previously 
extinguished heroin seeking (Banna, Back, Do, & See, 2010). 
We predicted a decrease in the maintenance of heroin-reinforced behaviour that would be 
translated by lesser active (and inactive) lever presses following an acute injection of OXT. 
Finally, we predicted a decrease in behavioural responses (lever presses) would be found in the 
yohimbine-induced reinstatement tests in rats being treated with the Low (0.50 μg/rat [ICV]; 0.30 
mg/kg [IP]) and high (2.50 μg/rat [ICV]; 1.00 mg/kg [IP]) doses of OXT compared to the rats 
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Experiment 1: Effects of acute exogenous oxytocin on heroin-taking behaviour in male rats 
 
Material & Methods 
Subjects 
The same group of Long Evans rats (n = 9; 300-350g) was used throughout the 
experiment. The rats were housed and treated as described in the general methods section. 
 
Surgical procedures 
Rats were implanted with intravenous (IV) silastic catheters to enable heroin self-




Operant-conditioning chambers: The operant-conditioning chambers used were identical 
to those described in the general methods section. 
Micro infusion pumps: Micro infusion pumps (Harvard Apparatus Model 11 Syringe 
Pump) were used to inject a chosen dose of OXT (or saline) prior to SA sessions or test days as 
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Drug 
Heroin (diacetylmorphine hydrochloride) and OXT lyophilized powder were dissolved as 
described in the general methods section.  
 
Procedure 
Before being placed in the operant-conditioning chambers, rats’ guide cannula placements 
were verified using an angiotensin II-induced (100 nmol; ICV) short latency (< 60 s) drinking 
response. All ICV cannulae were successfully verified. Once the PR self-administration training 
stabilized (> 5 infusions/session), rats were tested under four different conditions. Rats received 
two sham injections two days before each experiment started.  
Experiment 1A: Rats were kept on a heroin SA regimen of 0.10 mg/kg/infusion on a PR 
schedule of reinforcement as described in the general methods section. Rats were injected (ICV) 
with three doses of OXT over 3 test days (0.00, 0.50 and 2.50 μg/rat; counterbalanced order), 20 
min prior to their daily SA session. Tests were separated by one training day.  
Experiment 1B: A lower heroin SA dose (0.05 mg/kg/infusion) was used, and rats were 
tested with the same procedures and OXT doses as in Experiment 1A (ICV; 0.00, 0.50 and 2.50 
μg/rat; counterbalanced order).  
Experiment 1C: Rats were kept on a heroin SA regimen of 0.05 mg/kg/infusion on a PR 
schedule of reinforcement as described for Experiment 1B. However, OXT was administered IP 
20 min before the daily SA session (0.00, 0.30 and 1.00 mg/kg; counterbalanced order).  
Experiment 1D: Rats were re-trained on an FI-20 s schedule of reinforcement (one 5-h 
session/day) with a 0.05 mg/kg/infusion dose of heroin for 5 days. Next, rats were tested with 
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acute OXT injections 20 min before the first daily self-administration session (ICV; 0.00, 0.50 
and 2.50 μg/rat; counterbalanced order).  
 
Statistical Analyses 
All analyses were conducted using SPSS software (IBM, SPSS Statistics, version 22). 
Self-administration training: Data for all rats were analyzed using a repeated measures analysis of 
variance (ANOVA), with FI-20 s training day (1-10) or PR training day (11-17) as the within-
subject factor, and active and inactive lever responses as well as number of infusions as the 
dependent variables. The number of infusions earned in a session, which also represents the 
number of PR steps completed, was defined as the “breakpoint”. 
Test days: Number of infusions as well as active and inactive lever responses during the 
SA session following the acute OXT injection were analyzed using repeated measures ANOVAs, 
with OXT dose (Experiment 1A, 1B, 1D: Baseline, 0.00 [vehicle], 0.50 [low] and 2.50 [high] 
μg/rat; Experiment 1C: Baseline, 0.00 [vehicle], 0.30 [low] and 1.00 [high] mg/kg) as the within-
subject factor. Baseline was calculated as the average infusions and lever responses over the last 
five days of training. The critical cut-off point for statistically significant results was p ≤ .05. 
Time course: Number of infusions as well as active and inactive lever responses during 
the first 60 minutes of the SA session following an acute OXT injection were analyzed using 
two-way repeated measures ANOVAs, with OXT dose (Experiment 1D: 0.00 [vehicle], 0.50 
[low] and 2.50 [high] μg/rat) and time (6 x 10-min bins) as the within-subject factors. The critical 
cut-off point for statistically significant results was p ≤ .05. 
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Results 
 Final analysis for self-administration training included 9 rats. Experiments 1A and 1B 
included 9 rats while Experiments 1C and 1D included 8 rats. One rat was excluded due to the 
loss of its head cap following the training phase and was never tested, and a second rat died 
following an acute 2.50 μg/rat (ICV) OXT injection during Experiment 1B.  
The Greenhouse-Geisser correction was used when Mauchly’s test of sphericity 
assumptions was violated. 
 
Training 
Heroin infusion: Under FI-20 s, there was a statistically significant increase in heroin 
infusions over time, F(3.18, 28.59) = 7.46, p < .001 (Figure 1A). However, there was no 
statistically significant change in infusions number over training days under PR, F(6, 54) = 2.04, 
p = .076 (Figure 2A).  
Active lever responses: Similarly to heroin infusions, active lever responses increased 
throughout FI-20 s training (F(2.25, 20.25) = 3.41, p = .048; Figure 1B), while there was no 
change under PR (F(2.75, 24.74) = 1.85, p = .168; Figure 2B). 
Inactive lever responses: No statistically significant change was observed for inactive 
lever responses throughout both self-administration training regimes under FI-20 s (F(1.76, 
15.88) = 2.66, p = .106) or PR (F(1.05, 9.44) = 1.36, p = .275).  
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 Figure 1. Mean (± SEM) number of infusions (A) as well as active and inactive lever responses 
(B) made during heroin self-administration training by rats in Experiment 1 (n = 9). Rats self-
administered heroin (0.10 mg/kg/infusion) for three 3-h sessions under a fixed interval 20 s (FI-
20 s) schedule of reinforcement, over a 10-day period. Both infusion and active lever responses 
increased at a statistically significant level (p < .05) during training. There was no statistically 
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Figure 2. Mean (± SEM) number of infusions (breakpoint) (A) as well as active and inactive lever 
responses (B) made during heroin self-administration training by rats in Experiment 1 (n = 9). 
Rats self-administered heroin (0.10 mg/kg/infusion) for one 5-h session under a progressive-ratio 
(PR) schedule of reinforcement, over a 7-day period. There were no statistically different changes 
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Test days 
Experiment 1A: Acute treatment with OXT reduced breakpoint under PR schedule of 
reinforcement with 0.10 mg/kg/infusion of heroin, but only for the Low dose (Figure 3). There 
was a statistically significant effect for OXT dose on breakpoint (F(1.91, 15.28) = 4.09, p = .039, 
ηp2 = 0.34). Post-hoc t-tests with a Bonferroni-adjusted α = .008 revealed a statistically 
significant decrease in breakpoint in rats treated with a Low (0.50 μg/rat) OXT infusion versus 
the Baseline condition (t(9) = 2.31, p = 0.047) and the high (2.50 μg/rat) OXT dose, t(8) = -2.50, 
p = .037 (Figure 3). A similar pattern was observed for active lever responses; however, no 
statistically significant changes were found for active (F(1.06, 8.46) = 2.31, p = .165, ηp2 = 0.22; 
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Figure 3. Mean (± SEM) number of infusions earned (PR breakpoint) following an acute OXT 
injection (0.00 [vehicle], 0.50 [low] and 2.50 [high] μg/rat, ICV) in Experiment 1A (n = 9). Rats 
self-administered heroin (0.10 mg/kg/infusion) during a 5-h session under a progressive-ratio 
(PR) schedule of reinforcement. Baseline was calculated as the average number of infusions over 
the last five days of SA training under PR schedule. *p = .047 compared to Baseline condition. 
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Figure 4. Mean (± SEM) number of active (A) and inactive (B) lever responses following an 
acute OXT injection (0.00 [vehicle], 0.50 [low] and 2.50 [high] μg/rat, ICV) in Experiment 1A 
(n = 9). Rats self-administered heroin (0.10 mg/kg/infusion) during a 5-h session under a PR 
schedule of reinforcement. Baseline was calculated as the average number of active lever 
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Experiment 1B: No statistically significant changes in breakpoint under PR schedule of 
reinforcement with 0.05 mg/kg/infusion of heroin were found following OXT treatment (OXT 
dose: F(1.06, 0.52) = 0.59, p = .474, ηp2 = 0.07; Figure 5). Oxytocin infusions (ICV) seemed to 
reduce the number of active lever responses performed during the test session. Repeated 
measures ANOVA for active lever responses approached statistical significance (F(3, 24) = 2.89, 
p = .057, ηp2 = 0.27; Figure 6A). There were no statistically significant differences in inactive 
lever responses between the different treatment conditions (F(1.45, 11.59) = 1.72, p = .221, 
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Figure 5. Mean (± SEM) number of infusions (PR breakpoint) following an acute OXT injection 
(0.00 [vehicle], 0.50 [low] and 2.50 [high] μg/rat; ICV) in Experiment 1B (n = 9). Rats self-
administered heroin (0.05 mg/kg/infusion) during a 5-h session under a PR schedule of 
reinforcement. Baseline was calculated as the average number of infusions over the last five days 



























  31 
 
 
Figure 6. Mean (± SEM) number of active (A) and inactive (B) lever responses following an 
acute OXT injection (0.00, 0.50 and 2.50 μg/rat; ICV) in Experiment 1B (n = 9). Rats self-
administered heroin (0.05 mg/kg/infusion) during a 5-h session under a PR schedule of 
reinforcement. Baseline was calculated as the average number of active lever responses over the 
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Experiment 1C: No statistically significant differences were found for any of the analyzed 
variables following an acute IP administration of OXT to rats under a PR schedule of 
reinforcement with 0.05 mg/kg/infusion of heroin (OXT dose: Finfusions(3, 21) = 2.91, p = .059, 
ηp2 = 0.29; Factive(3, 21) = 2.34, p = .102, ηp2 = 0.25; and Finactive(3, 21) = 1.83, p = .172, 
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Figure 7. Mean (± SEM) number of infusions (PR breakpoint) following an acute OXT injection 
(0.00 [vehicle], 0.30 [low] and 1.00 [high] mg/kg; IP) in Experiment 1C (n = 8). Rats self-
administered heroin (0.05 mg/kg/infusion) during a 5-h session under a PR schedule of 
reinforcement. Baseline was calculated as the average number of infusions over the last five days 
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Figure 8. Mean (± SEM) number of active (A) and inactive (B) lever responses following an 
acute OXT injection (0.00 [vehicle], 0.30 [low] and 1.00 [high] mg/kg; IP) in Experiment 1C 
(n = 8). Rats self-administered heroin (0.05 mg/kg/infusion) during a 5-h session under a PR 
schedule of reinforcement. Baseline was calculated as the average number of active lever 
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Experiment 1D: No statistically significant effects were found for the OXT treatment on 
the number of heroin infusions under FI-20 s schedule of reinforcement (F(1.35, 9.42) = 1.15, 
p = .331, ηp2 = 0.14; Figure 9), the active lever responses (F(3, 21) = 1.23, p = .322, ηp2 = 0.15; 
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Figure 9. Mean (± SEM) number of infusions following an acute OXT injection (0.00, 0.50 and 
2.50 μg/rat; ICV) in Experiment 1D (n = 8). Rats self-administered heroin (0.05 mg/kg/infusion) 
for one 5-h session under a FI-20 s schedule of reinforcement. No statistically significant 
difference was found for any of the conditions. Baseline was calculated as the average number of 
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Figure 10. Mean (± SEM) number of active (A) and inactive (B) lever responses following an 
acute OXT injection (0.00, 0.50 and 2.50 μg/rat; ICV) in Experiment 1D (n = 8). Rats self-
administered heroin (0.05 mg/kg/infusion) for one 5-h session under a FI-20 s schedule of 
reinforcement. Baseline was calculated as the average number of active lever responses over the 
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Experiment 1D: Time course analysis for test days 
The number of infusions decreased quickly over the first 20 min of the daily 5-h session. 
There was a statistically significant effect of time (F(3, 35) = 10.20, p < .01, ηp2 = 0.59) and OXT 
dose (F(2, 14) = 5.29, p = .019, ηp2 = 0.43), but no OXT dose x time interaction effect (F(4.27, 
29.88) = 0.87, p = .498, ηp2 = 0.11; Figure 11). Post-hoc t-tests with a Bonferroni-adjusted 
α = .003 revealed that there was no statistically significant difference from the first to the last 10-
min bins for the low and high OXT doses while there were statistically significant differences 
between the 10 to 30-min (t(7) = 7.00, p < .01) bins and the 10 to 40-minute (t(7) = 5.16, p < .01) 
bins for the vehicle dose. 
 The number of active lever responses decreased quickly over the first 20 min of the 
session. There was a statistically significant effect of time (F(1.64, 11.45) = 18.53, p < .01) and 
OXT dose (F(2, 14) = 18.94, p < .01), but no OXT dose x time interaction effect (F(2.49, 
17,45) = 2.26, p = 0.125; Figure 12A). Post-hoc t-tests with a Bonferroni-adjusted α = .003 
revealed that there was no statistically significant difference from the first to the last 10-min bins 
for the high OXT dose, while there was a statistically significant decrease in the 10 to 30, 40, and 
50-min bin in the vehicle and in the 10 to 20, 30, 40, and 50-min bin in the low OXT dose. 
No statistically significant changes in inactive lever responses were found for time 
(F(1.06, 7.41) = 0.74, p = .426), OXT dose (F(1.02, 7.15) = 1.07, p = .336) or the interaction 
between time x OXT dose (F(1.05, 7.34) = 0.94, p = .367); see Figure 12B. 
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Figure 11. Mean (± SEM) number of infusions following an acute OXT injection (0.00 [vehicle], 
0.50 [low] and 2.50 [high] μg/rat, ICV) in Experiment 1D (n = 8). Rats self-administered heroin 
(0.05 mg/kg/infusion) during the first 60 minutes of their one 5-h session under a FI -20 s 
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Figure 12. Mean (± SEM) number of active (A) and inactive (B) lever responses following an 
acute OXT injection (0.00 [vehicle], 0.50 [low] and 2.50 [high] μg/rat, ICV) in Experiment 1D 
(n = 8). Rats self-administered heroin (0.05 mg/kg/infusion) during the first 60 minutes of their 
one 5-h session under a FI-20 s schedule of reinforcement. * Vehicle: p < .01 compared to the 10 
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Experiment 2: Effects of acute exogenous oxytocin on yohimbine-induced reinstatement of 
extinguished heroin seeking 
 
Material & Methods 
Subjects 
The same rats used in Experiment 1 were used in Experiment 2A (n = 7). In Experiment 
2B, only six rats completed both reinstatement tests. Rats were separated into two groups (OXT 
or saline). First, we calculated the mean of infusions as well as active and inactive lever presses 
obtained during the last 5 days of training (FI-20 s). Then, we counterbalanced the two groups 
and randomly chose the one in which the rats were assigned.  
 
Apparatus 
Operant-conditioning chambers: The operant-conditioning chambers used were identical 
to those described in the general methods section. 
Micro infusion pump: The micro infusion pump (Harvard Apparatus Model 11 Syringe 
Pump) was used to inject a chosen dose of OXT (or saline) prior to the reinstatement test as 
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Drug 
Yohimbine hydrochloride powder (Sigma-Aldrich, St-Louis, MO) was dissolved in sterile 
saline (2.00 mg/kg) and injected IP. Oxytocin lyophilized powder was dissolved and injected as 
described in the general methods section.  
 
Procedure 
Extinction: Following the completion of Experiment 1, rats were exposed to the same 
conditions and cues as described in the general methods section; however, no heroin was made 
available. The first day of extinction consisted of three 3-h extinction training sessions. 
Subsequently, extinction training included one 3-h daily session. Extinction training continued 
for at least 4 days and until the rats reached the extinction criterion of ≤ 15 active lever responses 
during the 3-h session.  
Yohimbine-induced reinstatement: Once the rats met the extinction criterion, they were 
tested for yohimbine-induced reinstatement on the next day. Rats were tested twice for 
reinstatement following an injection of saline and yohimbine (2.00 mg/kg; IP) in counterbalanced 
order, administered approximately 30 min before the test session. Exogenous OXT (Experiment 
2A: 2.50 μg/rat; Experiment 2B: 1.00 μg/rat; ICV) or saline were injected immediately before the 
session. Reinstatement tests were separated by at least one day of extinction training. Active and 
inactive lever responses were recorded during all sessions, and Baseline of active and inactive 
lever responses was calculated by averaging the lever responses made during the extinction 
session that preceded each test.  
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Statistical Analyses 
All analyses were conducted using SPSS software (IBM, SPSS Statistics, version 22). 
Separate repeated measures ANOVA were conducted for the active and inactive lever responses. 
The Greenhouse-Geisser correction was used when Mauchly’s test of sphericity assumptions was 
violated. Analyses included a between-subject factor of treatment (vehicle, OXT) and a within-
subject factor of condition (baseline, saline, yohimbine).  
The critical cut-off point for statistically significant results was p ≤ .05. 
 
Results 
 One rat was excluded due to poor health (Experiment 2A). A second rat died following an 
acute 2.50 μg/rat OXT injection (Experiment 2B).  
 
Experiment 2A 
Although the number of active lever presses increased following the yohimbine injection, 
the effect was not statistically significant (condition: F(1.11, 5.55) = 4.25, p = .087, ηp2 = 0.46; 
Figure 13). Moreover, no significant effect was found for the treatment (F(1, 5) = 0.02, p = .897, 
ηp2 = 0.004) or the treatment x condition interaction (F(1.11, 5.55) = .064, p = .833, ηp2 = 0.01; 
Figure 13A). 
 There was no statistically significant difference in inactive lever responses for either the 
condition (F(1.05, 5.25) = 3.73, p = .108, ηp2 = 0.43), treatment (F(1, 5) = 1.42, p = .287, 
ηp2 = 0.22) or the treatment x condition interaction (F(1.05, 5.25) = .182, p = .699, ηp2 =0.04; 
Figure 13B). 
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Figure 13. Mean (± SEM) number of active (A) and inactive (B) lever responses following an 
acute OXT (2.50 μg/rat) or saline injection (0.00 μg/rat; ICV; nsaline = 4, nOXT = 3). All rats were 
tested following a yohimbine (2.00 mg/kg) and saline injection (counterbalanced; IP). The 
reinstatement tests took place under extinction conditions for a 3-h session under a FI-20 s 
schedule of reinforcement. Baseline was calculated by averaging the lever responses made during 
the extinction session that preceded each test. No statistically significant difference was found for 
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Experiment 2B 
Yohimbine injection resulted in an increase in the number of active lever responses 
performed during the test session (condition: (F(2, 8) = 12.17, p < .01, ηp2 = 0.75; Figure 15). 
Post-hoc t-tests with Bonferroni-adjusted α = .017 revealed a statistically significant difference 
between the Baseline active lever and the yohimbine condition (t(6) = -3.74, p = .01). There was 
no statistically significant effect for the treatment x condition interaction (F(2, 8) = 2.20, 
p = .174, ηp2 = 0.35); however, the statistically significant yohimbine-induced increase in active 
lever responses seemed to be driven mostly by the OXT treated group. No significant effect was 
found for the treatment (F(1, 4) = 5.45, p = .08, ηp2 = 0.36) 
Moreover, there was no statistically significant difference in inactive lever responses for 
either the condition (F(2, 8) = 3.70, p = .073, ηp2 = 0.48) or the treatment x condition interaction 
(F(2, 8) = 0.48, p = .635, ηp2 = 0.11; see Figure 16). No significant effect was found for the 
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Figure 14. Mean (± SEM) number of active (A) and inactive (B) lever responses following an 
acute OXT (1.00 μg/rat) or saline injection (0.00 μg/rat; ICV; nsaline = 3, nOXT = 3). All rats were 
tested following a yohimbine (2.00 mg/kg) and saline injection (counterbalanced; IP). The 
reinstatement tests took place under extinction conditions for a 3-h session under a FI-20 s 
schedule of reinforcement. Baseline was calculated by averaging the lever responses made during 
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Experiment 3: Effects of acute exogenous oxytocin on anxiety-related behaviours in relation 
to locomotor activity 
 
Material & Methods 
Subjects 




Elevated plus maze: A wooden elevated plus maze (EPM) was used in Experiment 3A. 
The EPM consisted of a wooden plus sign-shaped maze, which was elevated 50 cm from the 
ground and had two closed arms (10 cm x 50 cm) and two open arms (10 cm x 50 cm), both of 
which separated by a neutral centre zone (10 cm x 10 cm). The open arms were located opposite 
of each other, resembling a platform, as they did not have arms. The closed arms, also located 
opposite each other, had a wall of 50 cm height each. 
Open field: An open field, made of metal and painted white (14 733.66 cm2), was used to 
conduct Experiment 3B. The open field consisted of a wide circular metallic arena (diameter of 
137 cm and walls 46 cm in height) and was placed in a brightly lit room with one food pellet 
weighing 5 g in the center. 
Micro infusion pump: The micro infusion pump (Harvard Apparatus Model 11 Syringe 
Pump) was used to inject 1.00 μg/rat of OXT (or saline) prior to the anxiety-related behavioural 
tests.  
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Drug 
Oxytocin lyophilized powder was dissolved and injected as described in the general 
methods section.  
 
Procedure 
Following Experiments 1 and 2, rats were tested for anxiety related-behaviours in 
procedures such as the elevated plus maze (EPM) and the open field. 
Elevated plus maze: Rats were individually transported inside a covered bucket to the 
testing room where they received an OXT injection (1.00 μg/rat; ICV) or saline, in 
counterbalanced order. Twenty minutes after the injection, rats were placed in the central zone 
with their head facing one of the closed or open arms (counterbalanced between rats and 
treatment conditions). A video camera was suspended above the EPM, and the rats’ behaviour 
was recorded over 5 minutes for off-line scoring. The test was performed in a brightly lit room 
with no outside interaction. An entry to an arm was defined as the condition in which the front 
paws and half the body of the rat were in one of the EPM arms (open or closed). The entire EPM 
was cleaned with 70 % ethanol solution between rats. Finally, four variables were scored: time 
spent in each arm (open, closed and central area) and number of entries in each arm. Forty-eight 
hours were given between tests in order for the drugs to wash out. 
Open field: Before testing the rats in the open field, the animals were food restricted to 
90% of their baseline body weight for 7 days in order to increase motivation to seek a food pellet 
that was placed in the middle of the open field. On test days, rats were brought into a dimly lit 
room where they were injected with OXT (1.00 μg/rat; ICV) or saline, in counterbalanced order. 
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Twenty minutes after the injection, rats were introduced into the open field. Rats were placed 
facing either the north, south, west or east positions of the arena and were then allowed to explore 
the open field for 10 minutes. A video camera was suspended above the open field apparatus in 
order to record movement for off-line scoring. Three variables were scored: latency to 
consumption of the food pellet, number of approaches to the food pellet, and number of moves 




All analyses were conducted using SPSS software (IBM, SPSS Statistics, version 22). 
Behaviours scored were analyzed using a paired-sample t-test with OXT condition (saline or OXT 
[1.00 μg/rat]) as the independent variable, and arm entries (EPM), time spent in each arm (EPM), 
latency to food consumption (open field), number of food approaches (open field), and number of 
moves per quadrant (open field) as the dependent variables. The critical cut-off point for 
statistically significant results was p ≤ .05. 
 
Results 
Elevated plus maze 
Open arm entries: Paired-sample t-tests revealed a statistically significant higher number 
of entries into the open arms under the 0.00 μg/rat compared to the 1.00 μg/rat OXT condition, 
t(6) = -3.03, p < .05, d = 0.28 (Figure 15A).  
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Time spent in open arms: Paired-sample t-tests revealed no statistically significant 
difference between the 0.00 μg/rat and the 1.00 μg/rat OXT condition, t(6) = -0.46, p = .665, 
d = 0.02 (Figure 15B). 
Closed arm entries: Paired-sample t-tests revealed no statistically significant difference 
between the 0.00 μg/rat and the 1.00 μg/rat OXT condition, t(6) = -0.082, p = .448, d = 3.38 
(Figure 16A). 
Time spent in closed arms: Paired-sample t-tests revealed no statistically significant 
difference between the 0.00 μg/rat and the 1.00 μg/rat OXT condition, t(6) = 1.04, p = .339, 
d = 0.23 (Figure 16B). 
Time spent in centre area: Paired-sample t-tests revealed no statistically significant 
difference between the 0.00 μg/rat and the 1.00 μg/rat OXT condition, t(6) = -1.60, p = .161, 














Figure 15. Mean (± SEM) of the number of entries (A) and the time spent (in s) (B) during a 5-
min observation in the open arms of the EPM following either a saline (0.00 μg/rat) or an acute 












































Figure 16. Mean (± SEM) of (A) the number of entries and (B) the time spent (in s) during a 5-
min observation in the closed arms of the EPM following either a saline (0.00 μg/rat) or an acute 
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Figure 17. Mean (± SEM) of the number of entries during a 5-min observation in the central area 
of the EPM following either a saline (0.00 μg/rat) or an acute OXT (1.00 μg/rat) injection (ICV; 
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Open field 
Latency to food pellet consumption: Paired-sample t-tests revealed no statistically 
significant difference between the saline and the acute OXT (1.00 μg/rat) in the latency to the 
consumption of the food pellet placed at the centre of the open field, t(6) = 1.58, p = .769, 
d = 0.02 (Figure 18). 
Number of approaches to central area of the field: Paired-sample t-tests revealed no 
statistically significant difference between the saline and the acute OXT (1.00 μg/rat) in the 
number of approaches attempted towards the centre of the open field, t(6) = 1.75, p = .131, 
d = 0.11 (Figure 19).  
Number of moves per quadrant: Paired-sample t-tests revealed no statistically significant 
difference between the saline and the acute OXT (1.00 μg/rat) in the number of moves per 
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Figure 18. Mean (± SEM) of latency to food consumption in (in s) between the saline (0.00 
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Figure 19. Mean (± SEM) number of approaches to the central area of the field during the 10-min 
observation period between the saline (0.00 μg/rat; n = 7) and OXT (1.00 μg/rat; n = 7) conditions. 
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Figure 20. Mean (± SEM) number of moves per quadrant during the 10-min observation period 
between the saline (0.00 μg/rat; n = 7) and OXT (1.00 μg/rat; n = 7) conditions. No statistically 
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Summary  
Contrary to our expectations, exogenous OXT did not attenuate heroin taking or heroin 
seeking in male rats, hence failing to replicate previous findings with both psychostimulant- and 
opiate-trained rats. Analysis of time course throughout the first hour of the self-administration 
test session in Experiment 1 revealed reduced lever pressing, which might be due to a non-
specific locomotor effect. In Experiment 2, oxytocin failed to reduce the anxiogenic effect 
induced by yohimbine, a pharmacological stressor, during reinstatement of extinguished heroin 
seeking. In addition, many cases of barrel rolling were observed following ICV injections of the 
highest dose of oxytocin used (i.e., 2.50 µg/rat). Experiment 3 aimed to investigate the effects of 
OXT on anxiety-related behaviours. Contrary to our hypothesis, OXT did not seem to have an 
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Introduction 
Contrary to reported findings, both central and systemic acute OXT injections have failed 
to show any noticeable impact on either the acquisition or the maintenance of heroin self-
administration (chapter 1). However, other studies have reported using a different procedure than 
the one introduced in chapter 1 by injecting OXT over a period of time (chronic injections) 
instead of acute injections.  
Unfortunately, very few studies implicating the effect of OXT on drug addiction have 
been conducted and such chronic administrations have stated inconsistent findings (Peters, 
Slattery, Uschold-Schimdt, Reber, & Neumann, 2014). Prior research has shown that chronic 
injections of OXT inhibited stimulated release of dopamine in the basal forebrain (Kovács et al., 
1986), key area for both OXT binding sites and drug-related behaviours (Sarnyai & Kovács, 
1994); and OXT dose-dependently decreased cocaine-induced hyperlocomotion and stereotyped 
grooming behaviour (Kovács et al., 1998). While recent studies have found that acute systemic 
OXT injections seem to positively impact (e.g., reduce intake or drug seeking) cocaine SA and 
cocaine reinstatement (see chapter 1), very little is known on the effects of chronic OXT 
injections on the motivation to consume and seek drugs. However, Westenbroek et al. (2013) 
have shown that OXT, chronically injected over 14 days, reduced motivation to self-administer 
methamphetamine in rats (females). 
In regards to our previous chapter, recent studies have shown how acute OXT could be of 
use in both drug intake and relapse prevention. As mentioned in chapter 1, OXT is well known to 
reduce anxiety-related behaviours. Peters et al.’s study (2014) aimed to investigate the impact of 
the neuropeptide in a clinically relevant animal paradigm modelling modern society’s chronic 
stress. They assessed the effect of chronic OXT (injected over 15 days; ICV) on chronic 
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subordinate colony housing, a model for chronic psychosocial stress, and reported that low doses 
of OXT could be beneficial and protect against such stress. 
In light of the very few studies that examined chronic OXT administration in relation to 
drug addiction, we investigated the role of chronically administered exogenous OXT on heroin 
self-administration on a progressive ratio schedule of reinforcement. Then, we aimed to 
investigate the behavioural impact of OXT on yohimbine-induced reinstatement of extinguish 
heroin seeking. As in chapter 1, rats were first trained to self-administer heroin for a period of 10 
days on a FI-20 s and were then put on a progressive ratio schedule for 7 days. Following self-
administration training, rats were assigned to three groups: vehicle (0.00 μg/rat; ICV), low (0.30 
μg/rat; ICV) or high (1.00 μg/rat; ICV) OXT. Rats receive their assigned dose of OXT for 14 
continuous days. Following this 14-day self-administration period on which the behavioural 
effect of OXT was measured, rats were kept in their operant-conditioning chambers for extinction 
training, as described in the general methods section. Finally, rats received either a yohimbine or 
a saline injection (2.00 mg/kg [IP]; counterbalanced) following their chronic OXT infusion on 
their reinstatement test day.   
We predicted that, over the 14-day OXT treatment period, we would see a decrease in 
heroin intake. We also predicted that a decrease in behavioural responses (lever presses) would 
be found in the yohimbine-induced reinstatement tests in rats being treated with the low and high 
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Experiment 1: Effects of chronic exogenous oxytocin on heroin-taking behaviour in male 
rats 
 
Material & Methods 
Subjects 
Long Evans rats (n = 17; 300-350g) were used. Rats were housed and treated as described 
in the general methods section. 
 
Surgical procedures 
Rats were implanted with intravenous (IV) silastic catheters to enable heroin self-
administration and intracerebroventricular (ICV) cannulae to allow OXT injections, as detailed in 
the general methods section.  
 
Apparatus 
Operant-conditioning chambers: The operant-conditioning chambers used were identical 
to those described in the general methods section. 
Micro infusion pumps: Micro infusion pumps (Harvard Apparatus Model 11 Syringe 
Pump) were used to inject a chosen dose of OXT (or saline) prior to SA sessions or test days as 
described in the general methods section.  
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Drug 
Heroin (diacetylmorphine hydrochloride) and oxytocin lyophilized powder were dissolved 
as described in the general methods section.  
 
Procedure 
Before being placed in the operant-conditioning chambers, rats’ guide cannula placements 
were verified using an angiotensin II-induced (100 nmol; ICV) short latency (< 60 s) drinking 
response. All ICV cannulae were successfully verified. Rats were first trained to self-administer 
heroin for 10 days under a fixed-interval 20 s schedule of reinforcement (FI-20 s; 3 x 3 h). Then, 
rats were switched to a PR schedule of reinforcement (one 5-h PR session per day) for 5 days 
until the PR self-administration training stabilized (> 5 infusions/session; see the general methods 
section). Following SA training, ICV exogenous oxytocin injections were administered over 14 
days before the daily self-administration session. Rats first received two sham injections over two 
days before the daily OXT treatment started. Next, rats were matched based on their average 
breakpoints and active lever presses, then split into three equivalent groups and injected (ICV) 




All analyses were conducted using SPSS software (IBM, SPSS Statistics, version 22).  
Self-administration training: Data for all rats were analyzed using a repeated measures 
analysis of variance (ANOVA), with FI-20 s training day (1-10) and PR training day (11-15) as 
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the within-subject factor, and active and inactive lever responses or number of infusions as the 
dependent variables. The number of infusions earned in a session, which also represents the 
number of PR steps completed, was defined as the “breakpoint”. 
Test days: Number of infusions as well as active and inactive lever responses during the 
SA session following daily OXT injection were analyzed using repeated measures ANOVAs, 
with a between-subject factor of OXT dose (0.00 [vehicle], 0.30 [low] and 1.00 [high] μg/rat) and 
a within-subject factor of day (1-14). The critical cut-off point for statistically significant results 
was p ≤ .05. 
 
Results 
 Two rats were excluded due to loss of their head cap and to poor health. Final analysis 
included 17 rats.  




Heroin infusions: There was a statistically significant increase in heroin infusions over 
time under the FI-20 s schedule, F(3.44, 61.93) = 20.68, p < .01 (Figure 21A), as well as for the 
PR schedule, F(4, 68) = 2.94, p = .027 (Figure 22A).  
Active lever responses: Similar to heroin infusions, active lever responses increased 
throughout both FI-20 s training (F(3.10, 55.79) = 7.02, p < .01; Figure 21B) and PR training 
(F(4, 68) = 3.01, p = .024; Figure 22B).  
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Inactive lever responses: No statistically significant change was observed for inactive 
lever responses throughout both self-administration training regimes under FI-20 s (F(3.06, 
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Figure 21. Mean (± SEM) number of infusions (A), active and inactive lever responses (B) during 
heroin self-administration training by rats in Experiment 1 (n = 17). Rats self-administered heroin 
(0.10 mg/kg/infusion) daily in three 3-h sessions under a fixed interval 20 s (FI-20) schedule of 
reinforcement, over a 10-day period. Both infusion and active lever responses increased at a 
statistically significant level (p < .05) during training. There was no statistically different change 
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Figure 22. Mean (± SEM) number of infusions (breakpoint) (A), active and inactive lever 
responses (B) during heroin self-administration training by rats (n = 17). Rats self-administered 
heroin (0.10 mg/kg/infusion) daily in one 5-h session under a progressive-ratio (PR) schedule of 
reinforcement, over a 5-day period. Both infusion and active lever responses increased at a 
statistically significant level (p < .05) during training. There was no statistically different change 
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Test days 
Heroin infusions: There was no statistically significant change in heroin infusions over the 
14-day period under PR schedule of reinforcement, Fday(1.37, 19.17) = 0.94, p = .374, ηp2 = 0.06 
(Figure 23). OXT administration had no statistically significant effect on the number of infusions 
obtained (FOXT dose(2, 14) = 0.59 , p = .568, ηp2 = 0.08).There also was no statistically significant 
interaction effect for day (14 days) x OXT dose (F(2.74, 19.17) = 1.13, p = .359, ηp2 = 0.16; 
Figure 23). 
Active lever responses: There was no statistically significant change in active lever 
responses over the 14-day period under PR schedule of reinforcement, Ftime(4.92, 68.88) = 1.57, 
p = .180, ηp2 = 0.10 (Figure 24). OXT administration had no statistically significant effect on the 
number of active lever responses (FOXT dose(2, 14) = 0.09, p = .918 , ηp2 = 0.001). Moreover, there 
was no statistically significant interaction effect for day x OXT dose (F(9.84, 68.88) = 1.88, 
p = .065, ηp2 = 0.21; Figure 24). 
Inactive lever responses: There was no statistically significant change in inactive lever 
responses over the 14-day period under PR schedule of reinforcement, Ftime(4.28, 59.90) = 1.74, 
p = .150, ηp2 = 0.11 (Figure 25). Furthermore, there was no statistically significant difference for 
OXT dose (F OXT dose(2, 14) = 1.90, p= .186, ηp2 = 0.18) or the interaction of day x OXT dose, 
F(8.56, 59.90) = 1.26, p = .281, ηp2 = 0.15; Figure 25). 
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Figure 23. Mean (± SEM) number of heroin infusions (breakpoint) during the 14 days of chronic 
OXT (0.00 [vehicle], 0.30 [low] and 1.00 [high] μg/rat) administration. Rats self-administered 
heroin (0.10 mg/kg/infusion) daily in one 5-h session under a PR schedule of reinforcement. 
There were no statistically significant differences in heroin infusions for any of the groups 
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Figure 24. Mean (± SEM) number of active lever responses during the 14 days of chronic OXT 
(0.00 [vehicle], 0.30 [low], and 1.00 [high] μg/rat) administration. Rats self-administered heroin 
(0.10 mg/kg/infusion) daily in one 5-h session under a PR schedule of reinforcement. There were 
no statistically significant differences in active lever responses for any of the groups (nVehicle = 5; 
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Figure 25. Mean (± SEM) number of inactive lever responses during the 14 days of chronic OXT 
(0.00 [vehicle], 0.30 [low], and 1.00 [high] μg/rat) administration. Rats self-administered heroin 
(0.10 mg/kg/infusion) daily in one 5-h session under a PR schedule of reinforcement. There were 
no statistically significant differences in inactive lever responses for any of the groups 
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Experiment 2: Effects of chronic exogenous oxytocin on yohimbine-induced reinstatement 
of extinguished heroin seeking 
 
Material & Methods 
Subjects 
The same rats used in Experiment 1 were used in Experiments 2A (n = 9) and 2B (n = 7). 
However, one rat was excluded due to poor health. 
 
Apparatus 
Operant-conditioning chambers: The operant-conditioning chambers used were identical 
to those described in the general methods section. 
Micro infusion pumps: Micro infusion pumps (Harvard Apparatus Model 11 Syringe 
Pump) were used to inject a chosen dose of OXT or saline, every day, prior to the rats’ 
reinstatement test, as described in the general methods section.  
 
Drug 
Yohimbine hydrochloride powder (Sigma-Aldrich, St-Louis, MO) was dissolved in sterile 
saline (2.00 mg/kg) and injected IP. Oxytocin lyophilized powder was dissolved and injected as 
described in the general methods section.  
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Procedures 
Extinction: Following the 14 days of testing under chronic OXT injections (Experiment 
1), rats underwent extinction while continuing to receive daily OXT injections, until they reached 
the extinction criterion (< 15 active lever responses per 5 h session). The rats were exposed to the 
same conditions and cues as described in the general methods section; however, no heroin was 
made available. Extinction training consisted of one daily 5-h session under PR schedule of 
reinforcement (Experiment 2A) or one 3-h session under FI-20 s schedule of reinforcement 
(Experiment 2B). Extinction training continued for at least 4 days and until the rats reached the 
extinction criterion of ≤ 15 active lever responses during one 5-h session under PR (Experiment 
2A) or during one 3-h session under FI-20 s (Experiment 2B). 
Yohimbine-induced reinstatement: Once the rats met the extinction criterion they were 
tested for yohimbine-induced reinstatement on the next day. The effects of chronic OXT 
injections on reinstatement were first tested in Experiment 2A over one 5-h PR session. Then, the 
effects of chronic OXT injections were tested in Experiment 2B over one 3-h FI-20 s. For both 
experiments, rats in each group were tested twice for reinstatement following an injection of 
saline or yohimbine (2.00 mg/kg; IP) in counterbalanced order, administered approximately 30 
minutes before the test session. OXT (0.00 [vehicle], 0.30 [low], and 1.00 [high] μg/rat; ICV) 
doses were injected immediately before the session. Reinstatement tests were separated by at 
least one day of extinction training. Active and inactive lever responses were recorded during all 
sessions, and Baseline of active and inactive lever responses was calculated by averaging the 
lever responses made during the extinction session that preceded each test.  
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Statistical Analyses 
All analyses were conducted using SPSS software (IBM, SPSS Statistics, version 22). 
Separate repeated measures ANOVAs were conducted for the active and inactive lever responses. 
First, lever responses (active and inactive; dependent variables) during the first 4 days of 
extinction training were analyzed with separate repeated measures ANOVA with day (1-4) as the 
within-subject factor and OXT dose as a between-subject factor (vehicle, low, and high). Second, 
reinstatement test analyses included a between-subject factor of OXT dose (vehicle, low, and 
high) and a within-subject factor of condition (baseline, saline, yohimbine). The critical cut-off 
point for statistically significant results was p ≤ .05. 
 
Results 
Final analysis for extinction training (> 4 days) included 9 rats (Experiment 2A). Two rats 
were then excluded due to poor health (experiment 2B).  
The Greenhouse-Geisser correction was used when Mauchly’s test of sphericity assumptions was 
violated. 
 
Experiment 2A: Extinction training  
Active lever responses: There was a statistically significant decrease in active lever 
responses over the 4 days of extinction training, Fday(3, 18) = 3.90, p = .026, ηp2 = 0.39 (see 
Figure 26A). Also, OXT administration had no statistically significant effect on the number of 
active lever presses: FOXT dose(2, 6) = 0.91, p = .452, ηp2 = 0.23. Moreover, no significant effect 
was found for the OXT dose x day interaction (F(6, 18) = 0.61, p = .717, ηp2 = 0.17). 
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Inactive lever responses: There was no statistically significant difference in inactive lever 
responses during extinction training for either the day (F(3, 21) = 0.82, p = .495, ηp2 = 0.04) or 
the OXT dose x day interaction (F(6, 21) = .61, p = .721, ηp2 = 0.14; see Figure 26B). Finally, 
OXT administration had no statistically significant effect on the number of inactive lever presses: 














Figure 26. Mean (± SEM) number of active (A) and inactive (B) lever responses during the 4 
days of extinction training with one daily 5-h session under a PR schedule of reinforcement. Rats 
continued to receive their daily OXT (0.00 [vehicle], 0.30 [low], and 1.00 [high] μg/rat) 
administration. There was no statistically significant decrease in active or inactive lever responses 
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Experiment 2A: Yohimbine-induced reinstatement 
Active lever responses: There was no statistically significant difference in active lever 
responses during yohimbine-induced reinstatement test for either the Condition (F(2, 12) = 3.31, 
p = .072, ηp2 = 0.39) or for the OXT dose x Condition interaction (F(4, 12) = 1.84, p = .186, 
ηp2 = 0.17; see Figure 27A). No significant effect was found for the OXT dose (F(2, 6) = 0.41, 
p = .683, ηp2 = 0.23). 
Inactive lever responses: There was no statistically significant difference in inactive lever 
responses following yohimbine-induced reinstatement tests for either the Condition (F(2, 
12) = 2.02, p = .175, ηp2 = 0.25) or the OXT dose x Condition interaction (F(4, 12) = 0.52, 
p = .721, ηp2 = 0.15; see Figure 27B). Moreover, no significant effect was found for the OXT dose 
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Figure 27. Mean (± SEM) number of active (A) and inactive (B) lever responses following 
chronic OXT injection (0.00, 0.30, 1.00 μg/rat; ICV; nVehicle = 4; nLow = 3; nHigh = 2). All rats were 
tested following yohimbine (2.00 mg/kg) and saline injections (counterbalanced order; IP). The 
reinstatement tests took place under extinction conditions during a 5-h session under a PR 
schedule of reinforcement. Baseline was calculated by averaging the lever responses made during 
the extinction session that preceded each test. No statistically significant difference was found for 
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Experiment 2B: Extinction training  
Active lever responses: There was no statistically significant difference in active lever 
responses during the extinction training, Fday(1.03, 4.11) = 2.84, p = .166, ηp2 = 0.42 (see Figure 
28A). No significant effect was found for the OXT dose x day interaction, either (F(2.05, 
4.11) = 0.36, p = .721, ηp2 = 0.15). Moreover, no significant effect was found for the OXT dose 
(F(2, 4) = 0.17, p = .848, ηp2 = 0.08). 
Inactive lever responses: There was no statistically significant difference in inactive lever 
responses during extinction training for either the day (F(3, 12) = 0.52, p = .678, ηp2 = 0.11) or 
the OXT dose x day interaction (F(6, 12) = .54, p = .770, ηp2 = 0.21; see Figure 28B). 
Furthermore, no significant effect was found for the OXT dose (F(2, 4) = 0.59, p = .594, 













Figure 28. Mean (± SEM) number of active (A) and inactive (B) lever responses during the 4 
days of extinction training for one 3-h session under a FI-20 s schedule of reinforcement. Rats 
continued to receive their daily OXT (0.00 [vehicle], 0.30 [low], and 1.00 [high] μg/rat) 
administration. There were no statistically significant differences in inactive lever responses for 
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Experiment 2B: Yohimbine-induced reinstatement 
Active lever responses: There was no statistically significant difference in active lever 
responses during yohimbine-induced reinstatement tests for either the Condition (F(1.06, 
4.23) = 2.57, p = .181, ηp2 = 0.39) or for the OXT dose x Condition interaction (F(2.12, 
4.23) = 0.52, p = .640, ηp2 = 0.20; see Figure 29A). No significant effect was found for the OXT 
dose (F(2, 4) = 0.19, p = .838, ηp2 = 0.08). 
Inactive lever responses: There was no statistically significant difference in inactive lever 
responses following yohimbine-induced reinstatement test for either the Condition (F(2, 
8) = 0.24, p = .792, ηp2 = 0.06) or the OXT dose x Condition interaction (F(4, 80) = 0.32, p = .860, 
ηp2 = 0.14; see Figure 29B). Moreover, no significant effect was found for the OXT dose (F(2, 
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Figure 29. Mean (± SEM) number of active lever responses following chronic OXT (0.00, 0.30, 
1.00 μg/rat; ICV; nVehicle = 1; nLow = 3; nHigh = 3). All rats were tested following yohimbine (2.00 
mg/kg) and saline injections (counterbalanced order; IP). The reinstatement tests took place under 
extinction conditions for a 3-h session under a FI-20 s schedule of reinforcement. Baseline was 
calculated by averaging the lever responses made during the extinction session that preceded each 
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Experiment 3: Effects of chronic exogenous oxytocin on stress-induced locomotor activity 
 
Materials & Methods 
Subjects 
The same rats (n = 14) used in Experiment 1 through Experiments 2A and 2B were used 
in Experiment 3. Unfortunately, two rats were excluded due to minor barrel rolling following an 
OXT injection (1.00 μg/rat; ICV) and testicle swelling (one rat), and a blockage of the ICV 
cannula (one rat). 
 
Apparatus 
Locomotor activity chamber: Locomotor activity was measured on the 28th day of 
consecutive OXT injections (0.00, 0.30, 1.00 μg/rat; ICV) with the help of infrared activity-
monitoring devices (TruScan Systems, Coulbourn Instruments, Whitehall, PA, USA) designed 
for rats. The apparatuses were made of clear polyethylene test chambers (39 cm x 42 cm x 50 cm) 
with 32 light-emitting diode photo detectors evenly spaced (2.50 cm) across the base of the 
apparatus. All locomotor boxes featured a slide-out floor for easier maintenance. The slide-out 
floor of each respective device was cleaned with ethanol (70 %) between each rat. Data were 
recorded using TruScan 2 (TS 2.0) software, and the following variables were selected for 
analysis: total distance travelled (in cm) and rest time. All rats were tested throughout the 
experiment in the same respective activity chamber at the same time of day they would self-
administer in operant-conditioning chambers. 
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Forced swim stress: Water buckets (diameter: 30 cm and depth: 40 cm) were filled with 
lukewarm water.  
Micro infusion pump: The micro infusion pump (Harvard Apparatus Model 11 Syringe 
Pump) was used to inject OXT (or saline) prior to SA sessions on test days as described in the 
general methods section. 
  
Drug 
Oxytocin lyophilized powder was dissolved and injected as described in the general 
methods section.  
 
Procedures 
Habituation: Rats were first introduced to their locomotor box for 30 min before receiving 
their daily OXT injection.  
Forced swim stress: Rats were gently dropped into their respective bucket of water and 
stayed there for a total of 10 min. Rats were then collected, dried off and put back into their 
respective locomotor activity box. 
Locomotor activity: Rats were put back in the same chamber they first habituated in and 
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Statistical Analyses 
All analyses were conducted using SPSS software (IBM, SPSS Statistics, version 22). 
Separate repeated measures ANOVAs were conducted for distance travelled and rest time using 
time as the within-subject factor (12 x 5-min bins) for the 60 minutes following the habituation 
and injection period. Analyses included a between-subject factor of OXT dose (vehicle, low, and 
high).  
Total distance travelled (in cm), and total rest time (dependent variables) were analyzed 
with separate one-way ANOVAs with OXT dose (0.00, 0.30, 1.00 μg/rat) as the between-subject 
factor.  
The critical cut-off point for statistically significant results was p ≤ .05. 
 
Results 
 Final analysis for stress-induced locomotor activity included 14 rats.  
The Greenhouse-Geisser correction was used when Mauchly’s test of sphericity assumptions was 
violated. 
 
Experiment 3: Locomotor activity (distance travelled) 
Distance travelled (by 5-min bins): Distance travelled over time decreased over the first 
five 5-min time bins, and then stabilized. There was a statistically significant effect of time 
(F(3.35, 36.84) = 3.57, p = .020, ηp2 = 0.26). There were no statistically significant difference for 
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either the OXT dose x time interaction (F(6.70, 36.84) = 1.99, p = .085, ηp2 = 0.27) or the effect of 
OXT dose (F(2, 11) = 0.15, p = .862, ηp2 = 0.03). 
Total distance travelled (cm): Homogeneity of variance (Levene’s Test) was violated 
(p = .002), thus the Welch-Satterthwaite correction was applied. The one-way ANOVA revealed 
no statistically significant decrease in the total distance travelled during the 60 min spent in the 
locomotor activity box following an OXT dose administration (F(2, 5.73) = 1.73, p = .258; see 
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Figure 30. Mean (± SEM) of distance travelled (cm) following an OXT injection (ICV; 
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Figure 31. Mean (± SEM) of total distance travelled (in cm) during the 60 min following an OXT 
injection (ICV; n0.00 μg/rat = 5; n0.30 μg/rat = 5; n1.00 μg/rat = 4). No statistically significant differences 
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Experiment 3: Locomotor activity (resting time) 
Rest time (by 5-min bins): There was no statistically significant difference in the time 
used by rats to rest in the locomotor box in relation to the time (F(4.60, 50.55) = 2.15, p = .079, 
ηp2 = 0.16) or the OXT dose x time interaction (F(9.19, 50.55) = 1.81, p = .088, ηp2 = 0.25). Also, 
there was no effect of OXT dose (F(2, 11) = 0.44, p = .658, ηp2 = 0.07; see Figure 32). 
Total rest time (in s): Homogeneity of variance (Levene’s Test) was violated (p < .001), 
thus the Welch-Satterthwaite correction was applied. The one-way ANOVA revealed no 
statistically significant decrease in the total rest time during the 60 minutes spent in the locomotor 
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Figure 32. Mean (± SEM) of rest time following an OXT injection (ICV; n0.00 μg/rat = 5; n0.30 
μg/rat = 5; n1.00 μg/rat = 4). The number of moves was compared starting at the 7th 5-min bin until the 
end of the locomotor activity task. No statistically significant difference was found for any of the 
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Figure 33. Mean (± SEM) of rest time during the 60 min following an OXT injection (ICV; 
n0.00 μg/rat = 5; n0.30 μg/rat = 5; n1.00 μg/rat = 4). No statistically significant difference was found for any of 
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Summary 
 In contrast to our expectations, no statistically significant changes were found during the 
14-day heroin SA following chronic injections of exogenous OXT in Experiment 1. We noted 
high variability and inconsistency in active lever responses over the treatment period, and OXT 
did not decrease the motivation for heroin self-administration.  
Experiment 2A checked whether OXT (low or high) would reduce yohimbine-induced 
reinstatement during a 5-h test under a PR schedule of reinforcement. Surprisingly, the low OXT 
dose (0.30 μg/rat) seemed to reduce this stress-induced reinstatement the most, but there was no 
statistically significant difference. Then, Experiment 2B tested yohimbine-induced reinstatement 
during a 3-h test under a FI-20 s schedule of reinforcement. In contrast to findings in Experiment 
2A, OXT consistently increased the active lever responses for both the low and high doses of 
OXT. However, no statistical differences were found.  
 Finally, the effects of exogenous OXT were tested in locomotor activity. Contrary to our 
expectations, OXT did not seem to change the distance travelled, nor did it change the rest time 




  93 
General Discussion 
This thesis first examined the effects of exogenous OXT on heroin self-administration 
under fixed-interval (20 s) and progressive schedules of reinforcement. Then, we investigated the 
role of OXT on yohimbine-induced reinstatement of previously extinguished heroin seeking. 
Given the gap in our understanding of the behavioural consequences of treatment with exogenous 
oxytocin on heroin taking and seeking, we explored the effects of acute (chapter 1) and chronic 
(chapter 2) OXT administration on heroin self-administration in male rats. 
Contrary to our expectations, both acute and chronic administration of exogenous 
oxytocin appeared to be ineffective in reducing heroin taking as well as in preventing or reducing 
yohimbine-induced reinstatement of extinguished heroin seeking. This is a surprising finding 
because previous studies had reported that OXT decreased heroin self-administration in heroin-
tolerant rats (Kovács et al., 1985; Kovács & Van Ree, 1985; Ibragimov et al., 1987), 
methamphetamine self-administration (Carson et al., 2010), and cocaine self-administration 
(Leong et al., 2016; Zhou et al., 2014). Moreover, OXT has also been shown to reduce 
reinstatement of morphine (Georgiou et al., 2015), of cocaine (Morales-Rivera et al., 2014; Zhou 
et al., 2014; Leong et al., 2016), and of methamphetamine seeking in rats (Baracz et al., 2014). In 
contrast to these prior findings, the results of our experiments did not confirm the expected 
correlation, as detailed in the following summary and discussion.
In chapter 1, we hypothesized that OXT treatment would result in lower “breakpoints” 
under progressive-ratio schedule of reinforcement or, in other words, lower motivation for heroin 
intake. However, no statistically significant changes in heroin intake were found under any of the 
schedules of reinforcement. Interestingly, a pattern of decreased rate of responses on the active 
lever seemed to emerge under FI-20 s in oxytocin-treated rats (high dose) over the initial 10 min 
of a heroin self-administration session. That period could then correspond to the peek of the very 
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short half-life of oxytocin (Gonser, 1995). Thus, this finding may suggest that oxytocin reduces 
rats’ locomotor activity and responses in their operant-conditioning chambers. However, this 
short-term decrease in rats’ active lever responses contrasts with the substantial decrease in 
heroin self-administration reported by Kovács et al. (1985) that lasted at least 24 h.  
In Experiment 2, contrary to our expectations, OXT did not reduce yohimbine-induced 
reinstatement and instead provoked, in a few instances, severe cases of barrel rolling. In fact, 
many cases of barrel rolling were observed, from short (3 to 20 s) and seemingly minor to long 
(over a minute) and lethal. Barrel rolls are characterized by unusual motor disturbances, ataxia, 
body swaying, spastic limbs abduction and so on (Diamant et al., 1993). It has been previously 
reported that some peptides, such as lysine vasopressin, arginine vasopressin, and OXT had 
induced similar responses when administered ICV (e.g., Kruse et al., 1977; Wurpel et al., 1985; 
Diamant et al., 1993) and were often fatal. Our results replicate the same deleterious effects as 
acute doses of arginine vasopressin, a similar neuropeptide to OXT also synthetized in the PVN 
and the SON, when centrally injected in the lateral ventricles of conscious rats (Kruse et al., 
1977; Wurpel et al., 1985; Diamant et al., 1993). While the underlying causes of barrel rolling are 
mostly unknown, some pharmacological compounds such as phenytoin and diazepam (anti-
epileptic drug) as well as muscle relaxant drugs (e.g., chlorpromazine) have been found to reduce 
such occurrences. Barrel rolling (or barrel rotation) has mostly been noted as an epileptic 
phenomenon considering the inhibiting effects induced by anti-epileptic medications (Diamant et 
al., 1993). Finally, following their results, Diamant et al. (1993) suggested that the V1 receptor, a 
receptor involved in cerebral water homeostasis regulation, was involved in barrel rolling. One 
plausible cause of those seizure-like incidents could be water intoxication in relation to high 
doses of OXT. While high doses of OXT were recommended for the treatment of missed 
abortions for women in the 1950s, water intoxication was quickly attributed to this type of 
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treatment since the first clinical case in 1962 (Ahmad et al., 1975). Interestingly, most water 
intoxication cases have been reported for acute doses of OXT in humans (Ahmad et al., 1975). As 
OXT and arginine vasopressin are also antidiuretic, it is possible that it creates a lower plasma 
sodium concentration, which in turns evokes hyponatremia, a severe water intoxication symptom 
(Ahmad et al., 1975). 
Finally, we tested the effect of OXT on anxiety-related tasks such as the elevated plus 
maze and an open field. Even though OXT has been acknowledged to regulate anxiety response 
and diminish anxious behaviours during those tasks (e.g., time spent and distance travelled in 
closed arms, grooming, and rearing) (Klenerová et al., 2011; Mak et al., 2012; Morales-Rivera et 
al., 2014), we were unable to replicate such results.  
In several studies (e.g., Klenerová et al., 2011, Mak et al., 2012), OXT acts as an 
anxiolytic agent to attenuate the fear reaction evoked in the EPM and open field tests. Although 
these studies have observed immediate behavioural modifications following an OXT injection, 
Klenerová et al. (2011) also reported a long-lasting attenuation of fear and anxiety when the 
animals were again exposed to stress 4 days later (treatment-free). Hence, it is possible that the 
rats in our experiments that received ICV and IP injections of OXT and vehicle 
(counterbalanced) had an attenuated response to stress on the second test, due to the long-lasting 
effect of OXT over time. Finally, when testing the effect of OXT on locomotor activity, our data 
did not show any statistically significant changes in the distance travelled and rest time in the 
locomotor box within a 90-min period, in contrast to findings from previous studies (Morales-
Rivera et al., 2014; Zhou et al., 2015)
In chapter 2, rats (3 groups; vehicle, low and high) received chronic injections of OXT 
over a 14-day period. This treatment regimen was based on a recent study that reported that 
chronic OXT administration (0.30 mg/kg, IP) could reduce motivation to self-administer 
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methamphetamine in female rats (Westenbroek et al., 2013). However, we were unable to 
replicate such results for both heroin intake and heroin seeking. It has previously been mentioned 
that the effects of chronic OXT are inconsistent, with a high dose being anxiogenic, while a low 
dose protected against some of the effects of chronic stress (Peters et al., 2014). The 
discrepancies found between our results and Westenbroek’s et al. (2013) study might be 
explained by investigating the effect of OXT on sex (males instead of female) and the type of 
drug (heroin instead of methamphetamine). Even though other studies (Leong et al., 2016; Zhou 
et al., 2015) suggest that OXT affects male as well as female rats, it seems that female rats are 
more responsive to OXT, at least in tests for locomotor activity, anxiety, and sucrose intake 
(Zhou et al 2015). 
 
Oxytocin, drug self-administration, and schedules of reinforcement 
 Interestingly, our results failed to replicate previous findings in studies that suggested 
oxytocin has the potential to decrease opiate (Kovács et al., 1985; Kovács & Van Ree, 1985; 
Ibragimov et al., 1987) and psychostimulant (Carson et al., 2010; Morales-Rivera et al., 2014; 
Zhou et al., 2015; Leong et al., 2016) drug self-administration. One possible explanation for the 
lack of effect of oxytocin on heroin self-administration is that the progressive-ratio schedule of 
reinforcement, in the way it was implemented here, might not be the best way to assess 
motivation for heroin intake. In fact, instead of providing rate measures that generate a stream of 
data with which it is possible to determine the time course of a drug action, the progressive ratio 
only provides a single data point for a whole self-administration session (Arnold & Roberts, 
1997). Recently, Zhou et al. (2014) reported that OXT statistically significantly reduced cocaine 
SA and active lever responses on FR1, FR5, and PR schedules of reinforcement. Arnold and 
Roberts (1997) suggest the possibility of fundamental and qualitative differences between 
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psychostimulant and opiate self-administration, and they hypothesized that while rats self-
administering heroin are highly motivated to self-administer the first injection of the session, they 
might lose interest for each subsequent heroin infusion. To address this caveat, a different 
progressive-ratio schedule has been developed to better assess the motivation to self-administer 
opiates (Roberts & Bennett, 1993), and this schedule produces breakpoints sensitive to 
manipulations of the unit dose of heroin (Arnold & Roberts, 1997).  
 A recent pilot study conducted in humans aimed to assess how intranasal OXT would 
affect heroin craving in patients receiving opioid replacement therapy compared to control 
individuals (Woolley et al., 2016). This pilot study in humans has found that while patients under 
opioid replacement therapy tolerated the OXT treatment well, it did not affect their cue-induced 
heroin craving. Surprisingly and, as problematic as our study was, the results obtained in both 
chapters seem to be closer to the human condition. However, many results might be dependent on 
the methodological issues that arose in comparison to all aforementioned studies. 
 
Methodological considerations 
Given the necessary limitations in scope of this thesis, it would first be recommended to 
replicate these experiments with a much bigger sample size in order to see if a clearer pattern 
emerges in comparison to our preliminary findings. Moreover, various studies have investigated 
the effect of oxytocin in both male and females suggesting that even though they often show 
similar effects in psychostimulant drugs self-administration and reinstatement (Leong et al., 
2016), some differences in locomotor activity and sucrose-seeking tests are still present (Zhou et 
al., 2015). Considering that very few recent studies have investigated the effect of OXT on 
opiate-related behaviours, it would be important to address the effects of OXT on opiate drugs 
intake and seeking in female rats.
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Another crucial consideration would be the oxytocin doses used during acute OXT 
injections in Experiments 1, 2 and 3 (chapter 1). Indeed, the higher dose used (2.50 μg/rat) caused 
multiple cases of barrel rolling that led to the death of an animal and to the severe deterioration of 
health in many other laboratory subjects. Thus, the doses used in chapter 2 (Walter et al., 1978) 
seemed to have less drastic consequences on health while still seemingly affecting the rats during 
their daily SA sessions or tests. In fact, while we were not able to observe a quantifiable 
anxiolytic effect for OXT, which plants doubt regarding the efficacy of the treatment in all our 
experiments, we were able to observe a strong effect of OXT on non-specific locomotor activity 
at the beginning of every SA session.
  
Conclusion 
In summary, the findings presented in this thesis suggest that there are no statistically 
significant changes in heroin SA or yohimbine-induced reinstatement for either acute or chronic 
treatment of oxytocin. While we could anecdotally report a reduction in locomotion following 
and OXT injection, it is very difficult to draw specific conclusions regarding the effects of OXT 
on heroin-related behaviours. Unless we conduct a broader follow-up study, we can only 
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